Brain Metastasases Clinical Trials

6 recruiting

Brain Metastasases Trials at a Glance

6 actively recruiting trials for brain metastasases are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Early Phase 1 with 1 trial, with the heaviest enrollment activity in Toronto, Houston, and Leiden. Lead sponsors running brain metastasases studies include Sunnybrook Health Sciences Centre, Fudan University, and M.D. Anderson Cancer Center.

Browse brain metastasases trials by phase

Treatments under study

About Brain Metastasases Clinical Trials

Looking for clinical trials for Brain Metastasases? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Brain Metastasases trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Brain Metastasases clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 1

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

Breast CancerMelanoma (Skin Cancer)Brain Metastasases
M.D. Anderson Cancer Center50 enrolled1 locationNCT06545682
Recruiting
Not Applicable

CSF and Blood Plasma Liquid Biopsy in Patients With Metastatic Solid Tumours and CNS Metastases or no CNS Metastases

Brain MetastasasesSolid Tumor MalignanciesLeptomeningeal Disease (LMD)
Sunnybrook Health Sciences Centre60 enrolled1 locationNCT07476781
Recruiting
Early Phase 1

A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases

Brain MetastasasesGlioblastoma (GBM)
Nader Sanai15 enrolled1 locationNCT07268053
Recruiting
Phase 3

Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases

Radiation ToxicityBrain MetastasasesHigh Grade Glioma (III or IV)+4 more
The Netherlands Cancer Institute408 enrolled5 locationsNCT06888817
Recruiting
Phase 2

Combined Gamma Knife/Linac Radiosurgery for Large Brain Tumors / Metastases

Brain MetastasasesBrain (Nervous System) CancersSRS
Sunnybrook Health Sciences Centre60 enrolled1 locationNCT07162246
Recruiting

AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases

NSCLC (Advanced Non-small Cell Lung Cancer)Brain Metastasases
Fudan University800 enrolled1 locationNCT06604689